Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medidiamond Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a single distinct examiner, ZOU, NIANXIANG, who is also the busiest examiner for the portfolio. The prosecution is currently focused within a single distinct art unit, indicating a concentrated technical and administrative scope for the company's pending matters. This singular focus means the company can dedicate its resources to a single examiner's feedback and requirements.
The busiest examiner pending count of 1 reflects the total number of pending office actions, showing that the entire pending portfolio is under the review of a single individual. This examiner, ZOU, NIANXIANG, will be the primary point of contact for the company's current patent efforts in the biotechnology sector. Because the work is limited to a single art unit, the company does not have to navigate the differing procedural norms of multiple patent office divisions. This streamlined prosecution environment allows for a highly targeted approach to overcoming any cited prior art.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18535827 | IMMUNOGENIC COMPOSITION AND USES THEREOF | ZOU, NIANXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18535827 | IMMUNOGENIC COMPOSITION AND USES THEREOF | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18535827 | IMMUNOGENIC COMPOSITION AND USES THEREOF | ZOU, NIANXIANG | 1671 | §103§112 | Final Rejection | — | Pending | Dec 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedidiamond Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nianxiang Zou has the most, with 1 of Medidiamond Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
